Lorcaserin for Weight Loss Management in Patients on Antipsychotics: A Pilot Study

Status unconfirmed · Phase 4

Conditions studied: Weight Gain

In brief

The purpose of this study is to determine whether lorcaserin is effective for weight reduction in patients with weight gain as a result of antipsychotic medications.

Key facts

Study ID

NCT01962402

Run by

Southern California Institute for Research and Education

People needed

15

Starts

2014-01-01

Last updated by the study team

2014-01-30

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients currently on atypical antipsychotics
• The patient's BMI is greater than or equal to 30 kg/m2 OR the patient's BMI is greater than or equal to 27 kg/m2 in the presence of at least one weight-related co-morbidity such as hypertension, type 2 diabetes mellitus, dyslipidemia, metabolic syndrome, obstructive sleep apnea, or degenerative joint disease such as osteoarthritis.
• Patient agreeable to follow up with provider at the scheduled appointments at week 1, week 2, week 4, week 8, week 12 and week 16 after initiation of medication.

You may not qualify if…

• Pregnancy in women or breastfeeding
• The patient has greater than mild aortic valve regurgitation, or moderate to greater mitral valve regurgitation
• Known hypersensitivity to lorcaserin
• The patient is taking another weight loss medication concurrently
• Dementia
• Age less than 18 or greater than 65
• No recent substance abuse within 3 months
• No suicidal ideation within 3 months
• Unable to give informed consent, unless patient is conserved, then the conservator can provide informed consent

Where it is running

• VA Long Beach — Long Beach, California, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.